Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01582477 · ClinicalTrials.gov registry record · Phase 4

TAP-patients With Robotic Assisted Lap Prostatectomy

A Phase 4 study of Analgesia and Prostatectomy, sponsored by Pacira Pharmaceuticals.

Completed
Registry status
Phase 4
Development phase
24
Enrollment target
1
Study location

NCT01582477 is a Phase 4 study of Analgesia and Prostatectomy that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 24 participants, below the 92-participant average among 19 other Analgesia trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01582477, a Phase 4 study of Analgesia and Prostatectomy, has completed, sponsored by Pacira Pharmaceuticals.

COMPLETED
Registry status
Phase 4
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to assess the safety and efficacy of EXPAREL when administered via infiltration into the transversus abdominis plane (TAP) to prolonged postsurgical analgesia in men undergoing robot-assisted laparoscopic prostatectomy.

Interventions

  • DRUG EXPAREL 20 mL
  • DRUG EXPAREL 40 mL

Study Locations (1)

Massachusetts

  • Steward St. Elizabeth's - Brighton

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2012-03
Est. Completion 2012-07
Phase Phase 4

Sponsor

Pacira Pharmaceuticals

88 total trials

What the Registry Record Tells You About NCT01582477

The ClinicalTrials.gov registry entry for NCT01582477 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 92-participant average among 19 other Analgesia trials with a reported enrollment target (74% lower). The listed sponsor is Pacira Pharmaceuticals, which has 88 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Analgesia appearing as the primary indexed condition, and to 2 interventions - of which EXPAREL 20 mL is the first listed.

NCT01582477 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01582477 about?

NCT01582477 is a clinical study titled "TAP-patients With Robotic Assisted Lap Prostatectomy". The purpose of the study is to assess the safety and efficacy of EXPAREL when administered via infiltration into the transversus abdominis plane (TAP) to prolonged postsurgical analgesia in men undergoing robot-assisted laparoscopic prostatectomy.

What is the current status of trial NCT01582477?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2012-03. Estimated completion is 2012-07.

What conditions does trial NCT01582477 study?

This clinical trial studies the following conditions: Analgesia, Prostatectomy, Postsurgical Pain.

What interventions are being tested in trial NCT01582477?

The interventions under investigation include: EXPAREL 20 mL (DRUG), EXPAREL 40 mL (DRUG).

Who is sponsoring clinical trial NCT01582477?

This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01582477 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Analgesia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.